Novel EGFR-TK Inhibitor EKB-569 Inhibits Hepatocellular Carcinoma Cell Proliferation by AKT and MAPK Pathways
Journal of Korean Medical Science
; : 1563-1568, 2011.
Article
en En
| WPRIM
| ID: wpr-227749
Biblioteca responsable:
WPRO
ABSTRACT
Epidermal growth factor receptor (EGFR)-targeted therapies have been effective in some cancers, but not in hepatocellular carcinoma (HCC). The aim of this study was to investigate the drug potential to overcome multi-drug resistance in HCC cells. Thirteen drug-sensitive HCC cells were assessed using the CCK-8 assay. G0-G1 arrest was measured by FACS. Western blot analysis was used to detect the key enzymes in both the Ras/Raf and PI3K pathways. When establishing the IC50 of HCC to several drugs, including EKB-569, sorafenib, erlotinib, gefitinib, pazopanib, and brivanib, SK-Hep1 cells treated with EKB-569 have shown the highest (72.8%-86.4%) G0-G1 arrest and decreased the phosphorylation of AKT and ERK at the protein level. We found that EKB-569 had higher efficacy in HCC, compared to first generation, reversible EGFR-TK inhibitors. Furthermore, the combination of sorafenib and EKB-569 showed a synergistic effect to inhibit proliferation of SNU-475, previously the most resistant cell to EGFR-TKIs. Therefore, novel EKB-569 in combination with sorafenib may be able to overcome HCC resistance to EGFR-TK inhibitors.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Fosforilación
/
Piridinas
/
Bencenosulfonatos
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Carcinoma Hepatocelular
/
Resistencia a Antineoplásicos
/
Proteínas Quinasas Activadas por Mitógenos
/
Línea Celular Tumoral
/
Proliferación Celular
/
Sinergismo Farmacológico
Límite:
Humans
Idioma:
En
Revista:
Journal of Korean Medical Science
Año:
2011
Tipo del documento:
Article